- Home
- CVSA vs AMRX Comparison
CVSA vs AMRX Comparison
Compare CVSA & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVSA | AMRX |
|---|---|---|
| Founded | 1987 | 2002 |
| Country | United States | United States |
| Employees | 4996 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.0B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CVSA | AMRX |
|---|---|---|
| Price | $130.31 | $16.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $150.00 | $15.60 |
| AVG Volume (30 Days) | 325.8K | ★ 2.2M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | N/A |
| Revenue This Year | $9.66 | $4.48 |
| Revenue Next Year | $6.58 | $7.13 |
| P/E Ratio | ★ N/A | $89.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $96.08 | $7.67 |
| 52 Week High | $135.96 | $17.86 |
Technical Indicators
Market Signals| Indicator | CVSA | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.07 | 68.98 |
| Support Level | $115.79 | $12.46 |
| Resistance Level | $132.60 | $17.86 |
| Average True Range (ATR) | 4.66 | 0.54 |
| MACD | 0.69 | -0.13 |
| Stochastic Oscillator | 70.11 | 54.92 |
Price Performance
Historical ComparisonAbout CVSA Covista Inc. Common Shares
Covista Inc is an American healthcare educator, serving more than 97,000 students and supported by a community of alumni across five accredited institutions. Through personalized, tech-enabled education powered by faculty and colleagues, it expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale.
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.